Psyence BioMed’s Strategic Collaboration with PsyLabs Yields Breakthrough in High-Purity Ibogaine Production
NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”) is pleased...
Clinical Trial
Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results
Received U.S. FDA approval for EMPAVELI® (pegcetacoplan) for treatment of patients 12 years and older with C3G and primary IC-MPGNAnnounced capped...
Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients
– Initial interim safety, tolerability, biomarker, and preliminary efficacy data expected in Q1 2026 –MIAMI, July 31, 2025 (GLOBE NEWSWIRE)...
BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in December
RESEARCH TRIANGLE PARK, N.C., July 31, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that its president and...
INmune Bio Inc. to Report Second Quarter 2025 Financial Results and Provide Corporate Update on Thursday, August 7th
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, July 31, 2025...
Amicus Therapeutics Announces Second Quarter 2025 Financial Results and Corporate Updates
Q2 2025 Total Revenue of $154.7M, up 18% at CER Galafold® Q2 Revenue of $128.9M, up 12% at CER Pombiliti®...
Unbuzzd Wellness Commences Reg D Capital Raise Campaign
Investment Opens for up to US$5.0 Million through a Regulation D 506(c) Offering to Fund Growth and Path to Possible...
Trial Evaluating Blood Test for 10 Cancers Reaches Major Milestone
SOUTHAMPTON, England, July 30, 2025 /PRNewswire/ -- MODERNISED (NIHR207538), a multi-site UK clinical study has passed a key milestone: over 450...
AI in Clinical Trials: Early Use Cases and Innovations, Upcoming Webinar Hosted by Xtalks
TORONTO, July 30, 2025 /PRNewswire/ -- In this free webinar, discover practical use cases of AI in clinical trials —...
Emerald Clinical Trials Confirms CEO Transition and Continuity Plan
SINGAPORE, July 30, 2025 /PRNewswire/ -- Emerald Clinical Trials, a leading global clinical research organization, today announced a leadership transition....
MAGENTIQ EYE Secures Series A Investment Led by aMoon to Drive the Future of AI-Powered Gastroenterology
Funding will support commercialization in the USA and Europe as well as continued development of MAGENTIQ COLO's advanced AI capabilities....
Arbor Biotechnologies Announces First Patient Dosed at Mayo Clinic in the redePHine Phase 1/2 Study of ABO-101, an Investigational Gene Editing Treatment for Primary Hyperoxaluria Type 1
- ABO-101 was well tolerated with no serious adverse events or dose-limiting toxicities reported in the 28-days following dosing -...
Moleculin Receives Notice of Intent to Grant New European Patent for Annamycin
– New patent enhances market position in Europe HOUSTON, July 30, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX)...
Tenaya Receives Positive Safety Reviews from Independent DSMBs to Advance Both TN-201 and TN-401 Gene Therapy Clinical Trials as Designed
Enrollment in Both Dose Cohorts of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Hypertrophic Cardiomyopathy (HCM) Complete; Follow-up Data...
Rein Therapeutics Enters into Agreements for up to $21 Million in Flexible Financing
- Financing designed to support Phase 2 IPF trial and pipeline advancementAUSTIN, Texas, July 30, 2025 (GLOBE NEWSWIRE) -- Rein...
NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer’s Disease Biomarkers at AAIC 2025
-- Pre-specified analysis shows obicetrapib significantly reduced absolute levels of plasma p-tau217, a key biomarker of Alzheimer’s disease pathology, in...
IMUNON Announces First Patient Dosed in Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer
Initiation of additional trial sites and patient enrollment activities ongoing with multiple patients in screening LAWRENCEVILLE, N.J., July 30, 2025...
Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference
NEEDHAM, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical...
Marker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference
HOUSTON, July 30, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T...
Immutep Quarterly Activities Report Q4 FY25
Media Release The pivotal TACTI-004 Phase III trial in first line non-small cell lung cancer (1L NSCLC) continues to build...